SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 CTCL Trial to Initiate Before End of 2024 Soligenix, Inc.

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

Soligenix's revenues for the quarter ended June 30, 2024 were less than $0.1 million as compared to $0.2 million for the ...

Australians with osteoporosis, a type of skin lymphoma, spinal muscular atrophy and type 2 diabetes will have access to new and expanded medicines ...

Soligenix (SNGX) announced the formation of a European Medical Advisory Board to provide additional medical/clinical strategic guidance to the ...

Phototherapy involves the use of ultraviolet light for the treatment of skin disease and many dermatologists have phototherapy units in their offices. With these units, ultraviolet light of ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Interferon alfa (a) is the subtype most commonly used and is the most well-studied for treating CTCL. Similar to insulin in administration, interferon-a is injected subcutaneously. Patients ...

Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the ...